Aiolos Bio
A clinical-stage biotech company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions.
Aiolos launched in October 2023 with an oversubscribed $245 million Series A investment co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments, with additional investment from RA Capital Management.
The company will advance its lead drug candidate, AIO-001, into a Phase II trial in moderate-to-severe asthma patients and is actively evaluating additional development opportunities.
Latest Aiolos Bio News & Features
9 January 2024
24 October 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze